ストックスクリーナーアプリを入手
4.67
1.97%
0.09
前日終値:
$4.58
開ける：
$4.58
24時間の取引高:
1.08M
Relative Volume:
1.29
時価総額：
$215.88M
収益：
$20.72M
当期純損益:
$-100.84M
株価収益率:
-1.7556
EPS:
-2.66
ネットキャッシュフロー:
$-78.56M
1週間 パフォーマンス:
-4.30%
1か月 パフォーマンス:
-25.99%
6か月 パフォーマンス:
-67.57%
1年 パフォーマンス:
-72.58%
1日の値動き範囲:
$4.48
$4.685
1週間の範囲:
$4.48
$5.15
52週間の値動き範囲:
$4.48
$36.25
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
名前
4 D Molecular Therapeutics Inc
セクター
電話
(510) 505-2680
住所
5858 HORTON STREET #455, EMERYVILLE
FDMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
4.67 | 215.88M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-13 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 開始されました | Morgan Stanley | Underweight |
| 2024-09-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 開始されました | Barclays | Overweight |
| 2024-02-07 | 再開されました | Goldman | Buy |
| 2023-10-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-18 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 開始されました | Chardan Capital Markets | Buy |
| 2023-01-30 | 開始されました | BMO Capital Markets | Outperform |
| 2022-11-18 | 開始されました | H.C. Wainwright | Buy |
| 2022-11-15 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-12 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 開始されました | Jefferies | Buy |
| 2022-01-04 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | BofA Securities | Buy |
| 2021-01-05 | 開始されました | Evercore ISI | Outperform |
| 2021-01-05 | 開始されました | Goldman | Neutral |
すべてを表示
4 D Molecular Therapeutics Inc (FDMT) 最新ニュース
Assenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - PR Newswire
FDMT stock touches 52-week low at $4.48 amid market challenges - MSN
4D Molecular Therapeutics' (FDMT) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Weiss Ratings Reiterates Sell (D-) Rating for 8X8 (NASDAQ:EGHT) - Defense World
Weiss Ratings Reiterates “Sell (D-)” Rating for 89bio (NASDAQ:ETNB) - Defense World
Weiss Ratings Reaffirms “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
JPMorgan Chase & Co. Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Equities Analysts Set Expectations for FDMT FY2029 Earnings - Defense World
FY2024 Earnings Estimate for FDMT Issued By Leerink Partnrs - Defense World
FY2029 Earnings Estimate for FDMT Issued By HC Wainwright - MarketBeat
Leerink Partnrs Has Bullish Outlook for FDMT FY2024 Earnings - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by Barclays PLC - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Lowered to “Market Perform” Rating by BMO Capital Markets - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given Buy Rating at HC Wainwright - Defense World
4D Molecular Therapeutics' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Morgan Stanley Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $6.00 - MarketBeat
4D Molecular Therapeutics stock hits 52-week low at $5.2 - Investing.com India
4D Molecular downgraded at BMO on limited population for wet AMD candidate - MSN
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Rating Lowered by BMO Capital Markets - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - MarketBeat
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts - Benzinga
Leerink cuts 4D Molecular Therapeutics price target following pipeline updates - Investing.com Australia
Leerink cuts 4D Molecular Therapeutics price target following pipeline updates By Investing.com - Investing.com South Africa
BMO Capital downgrades 4D Molecular Therapeutics stock to Market Perform, cites challenges - Investing.com Canada
BMO Capital downgrades 4D Molecular Therapeutics stock to Market Perform, cites challenges By Investing.com - Investing.com South Africa
4D Molecular Therapeutics refocuses on key drug candidates By Investing.com - Investing.com Australia
4D Molecular, FDA agree on phase 3 design for DME candidate - Seeking Alpha
FDMT4D Molecular Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
4D Molecular Therapeutics refocuses on key drug candidates - Investing.com India
4D Molecular Therapeutics Streamlines Pipeline, Advances Key Eye Disease & CF Programs with $506M Cash - StockTitan
Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry - News & Insights
4D Molecular's DME Drug Shows 86% Injection Reduction, Strong Vision Gains in Clinical Trial - StockTitan
Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Target Price at $42.56 - Defense World
Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $42.56 - MarketBeat
Geode Capital Management LLC Sells 24,346 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Barclays PLC Has $1.24 Million Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics stock hits 52-week low at $5.57 By Investing.com - Investing.com Canada
Fmr LLC Sells 1,012,123 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Analyzing Scholar Rock (NASDAQ:SRRK) and 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Critical Review: 4D Molecular Therapeutics (NASDAQ:FDMT) & Candel Therapeutics (NASDAQ:CADL) - Defense World
State Street Corp Boosts Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from S&P Biotechnology Select Industry Index - Marketscreener.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics - Benzinga
Bank of America Has Lowered Expectations for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price - MarketBeat
Short Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Increases By 8.8% - MarketBeat
4DMT Announces Landmark Publication of 4D-150 Preclinical - GlobeNewswire
4D Molecular's R100 Vector Shows 10X Potency Breakthrough in Landmark Eye Disease Study - StockTitan
4D Molecular Therapeutics stock hits 52-week low at $6.69 By Investing.com - Investing.com Canada
4D Molecular Therapeutics issues pre-funded warrant to RA Capital - Investing.com
4 D Molecular Therapeutics Inc (FDMT) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):